Research graph
References from Real-World Implementation and Clinical Outcomes of Mavacamten in an Underserved Urban Cohort With Obstructive Hypertrophic Cardiomyopathy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(20)31792-x
10.1016/s0140-6736(20)31792-x · External reference
10.1016/j.jacc.2022.04.048
10.1016/j.jacc.2022.04.048 · External reference
10.1093/eurheartj/ehae579
10.1093/eurheartj/ehae579 · External reference
Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program
2024 · External reference
10.1161/cir.0000000000001250
10.1161/cir.0000000000001250 · External reference
10.1093/phr/118.4.358
10.1093/phr/118.4.358 · External reference
10.7326/0003-4819-155-2-201107190-00005
10.7326/0003-4819-155-2-201107190-00005 · External reference
Eighteen-month real-world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population
10.1161/jaha.123.034069 · 2024 · External reference
10.1111/jce.70317
10.1111/jce.70317 · External reference
Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis
2026 · External reference
New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten
2026 · External reference
10.1016/j.jchf.2023.09.028
10.1016/j.jchf.2023.09.028 · External reference
Unresolved reference
External reference
10.1056/nejmra1710575
10.1056/nejmra1710575 · External reference
Unresolved reference
External reference
